---
authors:
- Ebell, Mark H
category: Clinical Review
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/36689986/
file_path: 2023/01/tirzepatide-helps-adults-with-obesity-without-diabetes-lose.md
issue: '1'
keywords:
- Gastric Inhibitory Polypeptide
- Obesity
- Body Weight
- Diabetes Mellitus, Type 2
- Humans
- Diabetes
- Adult
- Diabetes Mellitus
- Glucagon-Like Peptide-1 Receptor
- Tirzepatide
- Hypoglycemic Agents
last_updated: '2025-07-30'
mesh_terms:
- Adult
- Humans
- Body Weight
- Obesity
- Gastric Inhibitory Polypeptide
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Glucagon-Like Peptide-1 Receptor
- Tirzepatide
original_format: PubMed
pages: '99'
patient_population: Adults
peer_reviewed: true
pmid: '36689986'
processed_date: '2025-07-30'
publication_date: '2023-01-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-09'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Tirzepatide Helps Adults With Obesity Without Diabetes Lose 15% to 21% of Their
  Body Weight Over 72 Weeks.
topics:
- Diabetes Mellitus
- Endocrinology
- Family Medicine
- Metabolic Disorders
volume: '107'
publication_types: &id001
- Journal Article
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '36689986'
  title: Tirzepatide Helps Adults With Obesity Without Diabetes Lose 15% to 21% of
    Their Body Weight Over 72 Weeks.
  authors:
  - last_name: Ebell
    fore_name: Mark H
    initials: MH
    affiliation: University of Georgia, Athens, Ga.
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '107'
    issue: '1'
  publication_info:
    year: '2023'
    month: '01'
    full_date: '2023-01-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Adult
    major_topic: false
  - descriptor: Humans
    major_topic: false
  - descriptor: Body Weight
    major_topic: false
  - descriptor: Obesity
    major_topic: false
  - descriptor: Gastric Inhibitory Polypeptide
    major_topic: false
  - descriptor: Diabetes Mellitus
    major_topic: true
  - descriptor: Diabetes Mellitus, Type 2
    major_topic: true
  - descriptor: Hypoglycemic Agents
    major_topic: false
  - descriptor: Glucagon-Like Peptide-1 Receptor
    major_topic: false
  - descriptor: Tirzepatide
    major_topic: false
  publication_types: *id001
related_articles:
- pmid: '36689986'
  title: Tirzepatide Helps Adults With Obesity Without Diabetes Lose 15% to 21% of
    Their Body Weight Over 72 Weeks.
  authors:
  - name: Ebell MH
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2023 Jan
- pmid: '36617715'
  title: 'Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic
    Steatohepatitis.'
  authors:
  - name: Polyzos SA
    authtype: Author
    clusterid: ''
  - name: Goulas A
    authtype: Author
    clusterid: ''
  - name: Papaioannidou P
    authtype: Author
    clusterid: ''
  source: Curr Med Chem
  pubdate: '2023'
- pmid: '37880822'
  title: Impact on glycated haemoglobin and body weight changes after stopping tirzepatide
    for 4 weeks in the SURPASS-1 monotherapy trial.
  authors:
  - name: Rosenstock J
    authtype: Author
    clusterid: ''
  - name: Lee CJ
    authtype: Author
    clusterid: ''
  - name: Fernández Landó L
    authtype: Author
    clusterid: ''
  - name: Liu M
    authtype: Author
    clusterid: ''
  - name: Karanikas CA
    authtype: Author
    clusterid: ''
  - name: Thieu VT
    authtype: Author
    clusterid: ''
  source: Diabetes Obes Metab
  pubdate: 2024 Jan
- pmid: '36932808'
  title: Tirzepatide - A major breakthrough in the fight against obesity.
  authors:
  - name: Habiba U
    authtype: Author
    clusterid: ''
  - name: Iqbal A
    authtype: Author
    clusterid: ''
  - name: Kumar S
    authtype: Author
    clusterid: ''
  source: J Pak Med Assoc
  pubdate: 2023 Mar
- pmid: '37218275'
  title: Tirzepatide (Mounjaro) - a novel Pharmacotherapeutic Agent for Obesity.
  authors:
  - name: Tayyaba
    authtype: CollectiveName
    clusterid: ''
  - name: Siddiqui T
    authtype: Author
    clusterid: ''
  - name: Doultani PR
    authtype: Author
    clusterid: ''
  source: J Pak Med Assoc
  pubdate: 2023 May
---

# Tirzepatide Helps Adults With Obesity Without Diabetes Lose 15% to 21% of Their Body Weight Over 72 Weeks.

**Authors:** Ebell, Mark H

**Published in:** American family physician | Vol. 107, No. 1 | 2023-01-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/36689986/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Diabetes Mellitus, Endocrinology, Family Medicine, Metabolic Disorders

## MeSH Terms

Adult, Humans, Body Weight, Obesity, Gastric Inhibitory Polypeptide, Diabetes Mellitus, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor, Tirzepatide

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/36689986/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
